JPH0699313B2 - Macrophage and neutrophil activator - Google Patents
Macrophage and neutrophil activatorInfo
- Publication number
- JPH0699313B2 JPH0699313B2 JP2048396A JP4839690A JPH0699313B2 JP H0699313 B2 JPH0699313 B2 JP H0699313B2 JP 2048396 A JP2048396 A JP 2048396A JP 4839690 A JP4839690 A JP 4839690A JP H0699313 B2 JPH0699313 B2 JP H0699313B2
- Authority
- JP
- Japan
- Prior art keywords
- egg white
- macrophage
- infection
- macrophages
- neutrophil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000002540 macrophage Anatomy 0.000 title claims description 30
- 210000000440 neutrophil Anatomy 0.000 title claims description 23
- 239000012190 activator Substances 0.000 title claims description 5
- 235000014103 egg white Nutrition 0.000 claims description 41
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 39
- 102000002322 Egg Proteins Human genes 0.000 claims description 39
- 108010000912 Egg Proteins Proteins 0.000 claims description 39
- 210000000969 egg white Anatomy 0.000 claims description 36
- 208000015181 infectious disease Diseases 0.000 description 16
- 230000006870 function Effects 0.000 description 12
- 239000000843 powder Substances 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000003213 activating effect Effects 0.000 description 9
- 239000003242 anti bacterial agent Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000000242 pagocytic effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 208000035143 Bacterial infection Diseases 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 208000022362 bacterial infectious disease Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 241000282887 Suidae Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000000991 chicken egg Anatomy 0.000 description 5
- 230000007123 defense Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 244000144972 livestock Species 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000004100 Oxytetracycline Substances 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 230000002434 immunopotentiative effect Effects 0.000 description 4
- 239000004816 latex Substances 0.000 description 4
- 229920000126 latex Polymers 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 229960000625 oxytetracycline Drugs 0.000 description 4
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 4
- 235000019366 oxytetracycline Nutrition 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007813 immunodeficiency Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000003815 abdominal wall Anatomy 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000017924 poor diet Nutrition 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000272194 Ciconiiformes Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000000513 bioprotective effect Effects 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000003166 hypermetabolic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は卵白を含有するマクロファージ及び好中球活性
化剤に関する。更に詳しくは、生体の免疫能力の低下に
基づくと考えられる各種症患、各種病原微生物感染症の
予防・治療に有効な、卵白を含有する免疫増強・感染防
御剤に関する。TECHNICAL FIELD The present invention relates to a macrophage containing egg white and a neutrophil activator. More specifically, the present invention relates to an egg white-containing immunity-enhancing / infection-preventing agent which is effective in the prevention and treatment of various diseases and various pathogenic microbial infections that are considered to be due to the reduction of the immune capacity of the living body.
近年、抗菌性物質の開発が多くなされているにもかかわ
らず、生体側の宿主防御機能の低下が原因と考えられる
日和見感染症や癌などの症病が重要な課題となってい
る。Despite the recent development of antibacterial substances, opportunistic infections and cancers, which are considered to be caused by the deterioration of host defense function on the living body side, have become important issues.
生体の免疫能力の低下に基づくと考えられる各種症患、
例えば癌、各種病原微生物感染症などに対する免疫増強
剤あるいは癌の免疫療法剤は種々あるが、いずれも発熱
などの重篤な副作用が多く、決定的な免疫療法がないの
が現状である。Various illnesses that are thought to be due to a decrease in the immune capacity of the living body,
For example, there are various immunopotentiators or cancer immunotherapeutic agents against cancer, various pathogenic microbial infections and the like, but all of them have serious side effects such as fever and there is no definitive immunotherapy at present.
また、健康に対する人間の願望が高まり、個々の症病予
防を特異目的とした食品、即ち、新しい概念に基づく食
品の栄養・嗜好の機能に加え、生体調節機能を有する
“機能性食品”の研究が進められ、食品産業活性化の大
きな駆動力となりつつあり、今後の課題でもある。In addition, research on "functional foods" that have a biological regulation function in addition to the functions of nutrition and taste of foods based on a new concept, which has a special purpose to prevent individual diseases and diseases, as people's desire for health increases. Is being promoted and is becoming a major driving force for revitalizing the food industry, which is also an issue for the future.
一方、畜水産業界においても、国民の食生活における健
康志向に対応し、消費量が増大している中、家畜、家禽
又は養殖魚は集約化され、大規模経営が行われ、増殖或
いは過密飼育によって市場への需要に対応している。On the other hand, in the livestock and fisheries industry, livestock, poultry or farmed fish are centralized, and large-scale management is carried out in response to the health consciousness of the people's dietary habits and the consumption is increasing. To meet market demand.
しかしながら家畜などの過密飼育によるストレスや幼若
期における免疫不全による日和見感染症が多発してい
る。また、養殖魚の感染症の被害も増大傾向にある。However, opportunistic infections due to stress due to overcrowding of livestock and immunodeficiency during early life are common. In addition, the damage caused by infectious diseases of cultured fish is also increasing.
このような現状の中で免疫不全感染防御のために近年、
抗生物質の使用が多くなっている。しかし、大量の抗生
物質投与により畜水産物への残留の問題また耐性菌の増
加などが大きな社会問題となっている。Under these circumstances, in recent years to protect against immunodeficiency infection,
Increased use of antibiotics. However, administration of a large amount of antibiotics poses a serious social problem such as the problem of residues in livestock and marine products and the increase of resistant bacteria.
これに伴い、畜水産物の品質確保のための食鳥検査制度
など法的規制が厳しくなり、抗生物質の投与は適当でな
いとの気運が高まりつつある。このため抗生物質に代わ
る免疫不全・感染防御剤を有する予防方法の開発が望ま
れている。Along with this, legal regulations such as the poultry bird inspection system for ensuring the quality of livestock and marine products have become stricter, and there is growing concern that the administration of antibiotics is not appropriate. Therefore, development of a preventive method having an immunodeficiency / infection protective agent instead of an antibiotic is desired.
免疫機構は異種の抗原を識別し、処理排除するという生
体に備わった重要な機構であり、微生物などの病原性物
質の生体内への侵入あるいは癌細胞などの生体内で生じ
た異物に対して防御機構として働いている。The immune system is an important mechanism in the body that identifies and eliminates xenogeneic antigens, and protects against invasion of pathogenic substances such as microorganisms into the body or foreign substances generated in the body such as cancer cells. It works as a defense mechanism.
従って、宿主が本来持っている宿主防御能を増強する安
全性の高い免疫増強剤が期待されている。Therefore, highly safe immune enhancers that enhance the host defense originally possessed by the host are expected.
本発明者らは免疫増強・感染防御剤について鋭意検討し
た結果、卵白がマクロファージ及び好中球活性化作用を
有することを見出し、本発明を完成した。As a result of intensive studies on the immunopotentiating / infection-preventing agent, the present inventors have found that egg white has a macrophage and neutrophil activating effect, and completed the present invention.
即ち、本発明は、卵白を含有することを特徴とするマク
ロファージ及び好中球活性化剤を提供するものである。That is, the present invention provides a macrophage and neutrophil activator characterized by containing egg white.
以下、本発明を詳細に説明する。Hereinafter, the present invention will be described in detail.
本発明者らは生体防御系の増強を目的として感染防御に
主要な役割を果たすマクロファージの活性化を指環とし
て、生薬、食品など天然物質の生理活性成分につき、探
索した。The present inventors searched for bioactive components of natural substances such as herbal medicines and foods with the aim of activating macrophages that play a major role in defense against infection for the purpose of enhancing the biological defense system.
即ち、マクロファージには多様な機能がある(マクロフ
ァージの機能と機能測定法;日本細菌学会教育会編,薬
根出版,1985)。その基本は異物・老廃組織・微生物を
貧食し、処理することにあるが、細胞増強因子などのモ
ノカインを産出し、組織の修復を図り、自己及び好中
球、リンパ球の細胞分裂の補助やそれら細胞を活性化さ
せる働きを有する。That is, macrophages have various functions (functions of macrophages and method for measuring functions; edited by the Japanese Society of Bacterial Education, Yakune Shuppan, 1985). Its basic purpose is to phagocytose and process foreign substances, waste tissues, and microorganisms, but it also produces monokines such as cell-enhancing factors to repair tissues and assist in cell division of self, neutrophils, and lymphocytes. It has a function of activating those cells.
具体的には次の1)〜9)に示すような作用を有する。Specifically, it has the following actions 1) to 9).
1)異物・老廃物の処理 2)貧食・殺菌作用・ウィルスの不活化 3)炎症反応惹起 4)抗腫瘍作用 5)リンパ球機能の補助 6)免疫抑制 7)生体防御物質の産出 8)組織修復 9)脂質代謝への関与 本発明者らは卵白を用いてマウス、モルモット及び豚の
マクロファージ活性化作用、並びに豚好中球の活性化作
用を検討したところ、各種動物由来のマクロファージを
活性化することが判明した。また、卵白を経口投与さ
せ、マウスでの細菌感染に対する感染防御効果を検討し
たところ、大腸菌、黄色ブドウ球菌等、各種細菌感染に
対して感染抵抗性を著しく増強させることが明らかとな
った。1) Treatment of foreign substances / waste products 2) Poor diet / bactericidal action / virus inactivation 3) Induction of inflammatory reaction 4) Antitumor action 5) Supporting lymphocyte function 6) Immunosuppression 7) Production of bioprotective substances 8) Tissue repair 9) Involvement in lipid metabolism The present inventors examined the macrophage activating action of mouse, guinea pig and pig, and the activating action of porcine neutrophil using egg white, and found that macrophages derived from various animals were activated. It turned out to turn into. In addition, when egg white was orally administered and the infection protective effect against bacterial infection in mice was examined, it was revealed that the infection resistance to various bacterial infections such as Escherichia coli and Staphylococcus aureus was remarkably enhanced.
従って卵白がマクロファージ及び好中球活性化作用を有
し、免疫増強・感染防御効果を有することを見出した。Therefore, it was found that egg white has a macrophage and neutrophil activating effect, and has an immunopotentiating / infection-protecting effect.
本発明の作用機構は必ずしも明らかではないが、卵白の
摂取により消化管内で分解され、何らかの免疫増強物質
が生産されることによるものであると推定され、この免
疫賦活によって癌をはじめ広く細菌感染症、その他免疫
機能不全に基づく疾患(自己免疫疾患)に有用であると
推定される。Although the mechanism of action of the present invention is not necessarily clear, it is presumed that this is due to the fact that it is decomposed in the digestive tract by ingestion of egg white to produce some immunopotentiating substance, and this immunostimulation causes widespread bacterial infections including cancer. , It is presumed to be useful for other diseases caused by immune dysfunction (autoimmune diseases).
本発明で使用される卵白としては、生卵白、全卵末、卵
白末あるいは消化酵素で処理した画分や卵白を構成する
成分が入っているものであれば、特に制限はなく使用可
能である。The egg white used in the present invention is not particularly limited, as long as it contains raw egg white, whole egg powder, egg white powder or a component constituting egg white or a fraction treated with a digestive enzyme. .
本発明のマクロファージ及び好中球活性化剤を投与する
対象としては、特に制限はない。例えば、食品の栄養・
嗜考機能に加えて個々の疾病の予防を特異目的としてい
る生体調節機能を有する食品、いわゆる“機能性食品”
として用いることができる。The subject to which the macrophage and neutrophil activator of the present invention is administered is not particularly limited. For example, food nutrition
Foods with so-called "functional foods" that have a bioregulatory function for the purpose of preventing individual diseases in addition to the taste function
Can be used as
更に、抗生剤にみられる耐性菌の影響がなく、残留性の
問題もなく、安全かつ生体防御調節機能を有する飼料、
即ち、“機能性飼料”として、豚、鶏、牛、馬、羊など
の家畜や魚類、ペット(犬、猫)などに使用することも
できる。Furthermore, there is no influence of resistant bacteria found in antibiotics, there is no problem of persistence, and a feed that is safe and has a biological defense control function,
That is, it can be used as a "functional feed" for domestic animals such as pigs, chickens, cows, horses and sheep, fishes, pets (dogs, cats) and the like.
卵白の投与量は、卵白末の場合、体重1kg当たり、1日1
mg以上で、好ましくは10mg〜2g程度である。The dose of egg white is 1 day per kg of body weight for egg white powder.
It is at least mg, preferably about 10 mg to 2 g.
投与は通常経口的に摂取される。投与期間は各種病原微
生物感染症や癌などの疾病の予防・治療の時期に使用す
る。Administration is usually taken orally. The administration period is used at the time of prevention and treatment of various pathogenic microbial infections and diseases such as cancer.
本発明を実施する際は卵白又はその画分・成分を通常の
製剤化方法を用いて経口用の錠剤・カプセル剤・散剤・
顆粒剤・シロップ剤などとすることもできる。When practicing the present invention, the egg white or its fractions / ingredients are used for oral tablets / capsules / powder /
Granules and syrups can also be used.
即ち、経口投与用固形製剤を調製する場合には、主薬に
賦形剤、結合剤、崩壊剤、滑沢剤等を添加し、常法によ
り錠剤、カプセル剤、散剤、顆粒剤とする。That is, when preparing a solid preparation for oral administration, an excipient, a binder, a disintegrating agent, a lubricant and the like are added to the main ingredient, and tablets, capsules, powders and granules are prepared by a conventional method.
また、経口液状製剤を調製する場合は、主薬に緩衝剤、
矯味剤、安定剤を増加して常法によりシロップ剤等とす
る。また、卵白又はその画分・成分と抗菌剤又は抗悪性
腫瘍剤とを併用する際はそれぞれ別個に投与してもよい
し、必要によりこれらを合剤としてもよい。In addition, when preparing an oral liquid formulation, the main drug is a buffer,
A syrup or the like is prepared by increasing the amount of the corrigent and the stabilizer by a conventional method. When the egg white or its fraction / component and the antibacterial agent or the antineoplastic agent are used in combination, they may be administered separately, or if necessary, they may be combined.
また、水、牛乳、人工乳、健康食品など機能性食品など
の食物又は飼料に添加して投与してもよい。飼料の場合
は、飼料用原料やプレミックス素材としても利用でき
る。Further, it may be added to foods such as water, milk, artificial milk, functional foods such as health foods, or feed to be administered. In the case of feed, it can also be used as a feed material or premix material.
以下、本発明の効果を実験例により説明する。 Hereinafter, the effects of the present invention will be described with reference to experimental examples.
実験例1 鶏卵卵白のIn vitro添加によるマウス、モルモット及び
豚のマクロファージ活性化作用、並びに豚好中球の活性
化作用 マウスマクロファージの調整法: マウスをエーテル麻酔し、頚動脈切断による脱血後、冷
ハンクス液を5ml腹腔内に注入する。30秒間腹壁をマッ
サージしたのち、常在マクロファージを含むハンクス液
を回収した。遠心洗浄し15%マウス血清加MEM培地にて
2.5×106/mlに調整した。Experimental Example 1 Macrophage activating effect of mouse, guinea pig and pig, and porcine neutrophil activating effect by in vitro addition of chicken egg white. Preparation method of mouse macrophage: Mouse was anesthetized with ether, and blood was removed by carotid transection, and then cooled. Inject 5 ml of Hank's solution intraperitoneally. After massaging the abdominal wall for 30 seconds, Hanks' solution containing resident macrophages was collected. Centrifuge and wash in MEM medium containing 15% mouse serum
Adjusted to 2.5 × 10 6 / ml.
モルモットマクロファージ調整法: 4日前に1%カゼインNa生食水10mlを腹腔内に注射した
モルモット(ハートレイ系雌:体重300g)をエーテル麻
酔し、頚動脈切断による脱血後、冷ハンクス液を50ml腹
腔内に注入する。30秒間腹壁をマッサージしたのち腹腔
浸出細胞を含むハンクス液を回収する。遠心洗浄し、15
%モルモット血清加MEM培地にて2.5×106/mlに調整し
た。Guinea pig macrophage preparation method: Guinea pigs (Hartley female: body weight 300 g) injected intraperitoneally with 10 ml of 1% casein Na saline 4 days ago were anesthetized with ether, and blood was removed by carotid artery transection. inject. After massaging the abdominal wall for 30 seconds, Hanks' solution containing peritoneal exudate cells is collected. Centrifuge washed, 15
The concentration was adjusted to 2.5 × 10 6 / ml with MEM medium containing% guinea pig serum.
豚マクロファージ(末梢血単球)及び好中球の調整法: 豚の腋下大静脈より末梢血10ml(ヘパリン25単位/ml含
有)を採血し6%(W/V)デキストラン生食水(分子量6
6900)を3ml混和し37℃30分間放置して白血球層を分離
する。これをフィコールパック10mlの上層に静かに注ぎ
1900rpm,4分間遠心して単球及び好中球分画を得た。単
球分画は、非付着細胞(リンパ球)を除き2.5×106mlに
調整してマクロファージとした。好中球分画は0.85%塩
化アンモニウム液で赤血球を破壊し遠心洗浄して好中球
を採取した。15%豚血清加MEM培地にて2.5×106/mlに調
整した。Preparation method of porcine macrophages (peripheral blood monocytes) and neutrophils: 10 ml of peripheral blood (containing 25 units / ml heparin) was collected from the axillary vena cava of pigs, and 6% (W / V) dextran saline (molecular weight 6
6900) is mixed with 3 ml and left at 37 ° C for 30 minutes to separate the white blood cell layer. Gently pour this on top of 10 ml of Ficoll pack
After centrifugation at 1900 rpm for 4 minutes, monocyte and neutrophil fractions were obtained. The monocyte fraction was adjusted to 2.5 × 10 6 ml except for non-adherent cells (lymphocytes) and used as macrophages. For the neutrophil fraction, erythrocytes were disrupted with 0.85% ammonium chloride solution and centrifuged to collect neutrophils. The concentration was adjusted to 2.5 × 10 6 / ml with MEM medium containing 15% pig serum.
マウス、モルモット及び豚マクロファージの活性化測
定: マクロファージが活性化するとグルコースが代謝亢進す
る。それ故、培養液中のグルコースの消費を測定するこ
とによってマクロファージの活性化を測定できる。Activation measurement of mouse, guinea pig and pig macrophages: When macrophages are activated, glucose is hypermetabolic. Therefore, macrophage activation can be measured by measuring glucose consumption in culture.
卵白末を100,10,1μg/mlの割合でマクロファージ培養液
にin vitroで添加し5%CO2下、37℃,48時間インキュベ
ーション後、培養液中のグルコース含量をグルコース測
定試薬(グルコース−B−テストワコー:和光純薬)を
用いて測定した。Egg white powder was added in vitro to macrophage cultures at a rate of 100, 10, 1 μg / ml and incubated at 37 ° C for 48 hours under 5% CO 2 and then the glucose content in the cultures was determined by the glucose measurement reagent (glucose-B -Test Wako: Wako Pure Chemical Industries, Ltd.).
すなわち培養上清20μを小試験管にとりグルコース測
定用酵素液1.5mlを加え、37℃,30分間インキュベート
後、505nmで比色した。マクロファージの活性化index
(MAI)は次の式で計算した。That is, 20 μl of the culture supernatant was placed in a small test tube, 1.5 ml of an enzyme solution for glucose measurement was added thereto, the mixture was incubated at 37 ° C. for 30 minutes, and then colorimetry was performed at 505 nm. Macrophage activation index
(MAI) was calculated by the following formula.
結果を表1に示す。 The results are shown in Table 1.
表1から明らかな如く、卵白末を100,10,1μg/mlの割合
でマウス、モルモット及び豚マクロファージに添加する
とグルコースの消費が著しく亢進し各種動物由来マクロ
ファージを活性化させた。 As is clear from Table 1, when egg white powder was added to mice, guinea pigs and pig macrophages at a rate of 100, 10, 1 μg / ml, glucose consumption was markedly enhanced and macrophages derived from various animals were activated.
豚好中球の活性化測定法: ラブテックチャンバー (4チャンバー)に豚好中球
(2.5×106/ml)を0.5ml入れ卵白末を100μg/mlの割合
で添加し5%CO2下、37℃,3時間培養した。反応終了
後、オプソニン化したラテックス粒子(0.81μm)を0.
05ml添加し45分間貧食させた。上清を捨てよく洗浄しメ
タノール固定しギムザ染色した。鏡検にて貧食率が亢進
しているかどうか検討した。Pig neutrophil activation assay: Labtech chamber (4 chambers) pig neutrophils
(2.5 x 106/ ml) 0.5 ml of egg white powder to 100 μg / ml
Added in 5% CO2The cells were cultured at 37 ° C for 3 hours under End of reaction
After that, the opsonized latex particles (0.81 μm) were added to 0.
05 ml was added and it was made to eat for 45 minutes. Discard the supernatant and wash thoroughly.
It was fixed with tanol and stained with Giemsa. Poor diet rate increased on microscopic examination
I examined whether I was doing it.
結果を表2に示す。 The results are shown in Table 2.
表2から明らかな如く、卵白末を100μg/mlの割合で豚
好中球に添加した結果、好中球のラテックス粒子に対す
る貧食能を著しく亢進させた。 As is clear from Table 2, egg white powder was added to pig neutrophils at a rate of 100 μg / ml, and as a result, the phagocytic ability of neutrophils to latex particles was remarkably enhanced.
上記のように卵白は生体防御機構において重要な役割を
担うマクロファージ及び好中球を活性化させ免疫増強効
果を有することがここに新しく発見された。As described above, it was newly discovered here that egg white activates macrophages and neutrophils that play an important role in the biological defense mechanism and has an immunopotentiating effect.
実験例2 鶏卵卵白の経口投与によるマウスでの細菌感染に対する
感染防御効果 In vivoでマウスに卵白を経口投与し各種細菌感染に対
する感染防御効果を検討した。Experimental Example 2 Oral administration of chicken egg white to prevent infection against bacterial infection in mice In vivo, egg white was orally administered to mice to examine the protective effect against various bacterial infections.
slc:ICR系雄性マウス(5〜6週令、体重25〜33g)に卵
白又は卵白画分或いは成分の表3に示す量を1日3回経
口投与し、24時間後に臨床由来大腸菌(Escherichia co
li)を5.0×107/マウスの菌量で静脈内接種し感染後7
日目の生存数より生残率を求めた。また比較として大豆
蛋白及びスキムミルクを経口投与した場合についても同
様に生残率を求めた。結果を表3に示す。slc: ICR male mice (5-6 weeks old, body weight 25-33 g) were orally administered with egg white or egg white fractions or the amounts shown in Table 3 three times a day, and 24 hours later, clinically-derived Escherichia coli (Escherichia co
li) was inoculated intravenously with a bacterial amount of 5.0 × 10 7 / mouse and infected 7
The survival rate was calculated from the number of survivors on the day. For comparison, the survival rate was also obtained in the case of oral administration of soy protein and skim milk. The results are shown in Table 3.
また臨床由来大腸菌(Escherichia coli)に代えて臨床
由来黄色ブドウ球菌(Staphylococcusaureus)を3.8×1
07/マウスの菌量で静脈内に接種し感染後の延命効果及
び14日後までの生残率を求めた。結果を図1に示す。In addition, instead of clinically-derived Escherichia coli, clinically-derived Staphylococcus aureus 3.8 x 1
The survival effect after infection and the survival rate up to 14 days after inoculation were intravenously inoculated at a bacterial load of 0 7 / mouse. The results are shown in Fig. 1.
表3及び図1の結果より卵白及び卵白画分または成分は
各種細菌感染に対して感染抵抗性を著しく増強すること
が明らかとなった。 From the results of Table 3 and FIG. 1, it was revealed that egg white and egg white fractions or components markedly enhance infection resistance against various bacterial infections.
また、抗生物質オキシテトラサイクリン(OTC)との併
用実験を行った。即ち、卵白を投与して一日後に大腸菌
を感染させ、感染と同時に抗生物質オキシテトラサイク
リンを経口投与して併用効果を検討した。結果を図2に
示す。In addition, a combination experiment with the antibiotic oxytetracycline (OTC) was conducted. That is, E. coli was infected one day after the administration of egg white, and at the same time as the infection, the antibiotic oxytetracycline was orally administered and the combined effect was examined. The results are shown in Figure 2.
図2に示した如く、卵白と抗生物質との併用は、抗生物
質の少量でも著しい生残率の上昇を示し、抗生物質の量
を減らすことができ、かつ相乗効果が認められた。As shown in FIG. 2, the combined use of egg white and antibiotics showed a marked increase in survival rate even with a small amount of antibiotics, the amount of antibiotics could be reduced, and a synergistic effect was observed.
このような例は他になく新しい発見である。This is a new discovery like no other.
実験例3 鶏卵卵白の経口投与によるマクロファージの活性化作用 slc:ICR系雄性マウス(5〜6週令、体重25〜33g)に卵
白末の表4に示す量を1日3回経口投与し、24時間後に
カーボンクリアランステストを行いマクロファージの活
性化の有無を見た。Experimental Example 3 Macrophage activation by oral administration of chicken egg whites slc: ICR male mice (5-6 weeks old, body weight 25-33g) were orally administered with the amount of egg white powder shown in Table 4 three times a day. After 24 hours, a carbon clearance test was performed to see if macrophages were activated.
カーボンクリアランステストはコロイドカーボンの血中
からのクリアランスを指標として、肝、脾のマクロファ
ージ機能を測定するものである。カーボン(ペリカン社
製)を160mg/kgの割合で尾静脈に注入した。注入後3,6,
9,12,15分後に後眼窩静脈叢より2μを採血し小試験
管中で2mlの0.1%炭酸ナトリウムと混合した。これを66
0nmの波長で吸光度を測定した。横軸に時間(分)を、
縦軸に吸光度の対数値をとり3分ごとの値をプロットす
る。この直線の勾配(貧食指数K)を求め肝、脾の重量
を補正して訂正貧食指数(α)を算出した。The carbon clearance test measures the macrophage function of the liver and spleen using the clearance of colloidal carbon from the blood as an index. Carbon (manufactured by Pelican) was injected into the tail vein at a rate of 160 mg / kg. 3,6 after injection
After 9,12, and 15 minutes, 2 μm of blood was collected from the retroorbital venous plexus and mixed with 2 ml of 0.1% sodium carbonate in a small test tube. 66 this
Absorbance was measured at a wavelength of 0 nm. Time (minutes) on the horizontal axis,
The logarithmic value of the absorbance is taken on the vertical axis, and the value every 3 minutes is plotted. The gradient of this straight line (phagocytosis index K) was determined, and the corrected dietary index (α) was calculated by correcting the weight of the liver and spleen.
結果を表4に示す。 The results are shown in Table 4.
表4に示すように卵白投与群はいずれも貧食指数K及び
訂正貧食指数α値が対照に比べ大きくなり、卵白の経口
投与によってマウスマクロファージの貧食能が亢進し活
性化されていることが明らかとなった。 As shown in Table 4, in all of the egg white administration groups, the phagocytic index K and the corrected phagocytic index α value were larger than those of the control, and oral phagocytic administration of egg white promoted and activated the phagocytic ability of mouse macrophages. Became clear.
実験例4 鶏卵卵白の経口投与による豚の末梢血好中球の活性化作
用 卵白末500mg/kgを豚(体重約20kg)4頭に飼料添加して
1日後の末梢血好中球のラテックス粒子に対する貧食能
が亢進するかどうか検討した。Experimental Example 4 Oral administration of chicken egg whites to activating peripheral blood neutrophils in pigs Egg white powder 500 mg / kg was added to 4 pigs (body weight: about 20 kg) as a feed, and latex particles of peripheral blood neutrophils were obtained one day later. It was examined whether or not the poor phagocytic ability to
末梢血好中球の分離はフィコールパック比重遠心法によ
り分離し、ラテックス粒子に対する貧食能は実験例1で
述べた方法により実施した。Peripheral blood neutrophils were separated by Ficoll-pack specific gravity centrifugation, and the phagocytic ability to latex particles was performed by the method described in Experimental Example 1.
結果を表5に示す。The results are shown in Table 5.
表5に示すように豚に卵白を飼料添加して摂取させるこ
とにより末梢血好中球の貧食能が著しく亢進し活性化し
ていることが明らかとなった。 As shown in Table 5, it was clarified that the dietary intake of egg white in pigs markedly enhanced and activated the phagocytic capacity of peripheral blood neutrophils.
以上の実験例の結果より、鶏卵卵白の免疫増強・感染防
御効果が明らかとなり生体の免疫能力の低下に基づくと
考えられる各種疾患や各種病原微生物感染症(細菌、マ
イコプラズマ、ウイルス、真菌、原虫など)、癌などの
予防、治療剤、まは機能性食品及び機能性飼料(飼料添
加)素材として期待される。From the results of the above experimental examples, various effects and various pathogenic microbial infectious diseases (bacteria, mycoplasma, viruses, fungi, protozoa, etc.) which are considered to be based on the immune enhancement / infection protection effect of chicken egg white, which is considered to be based on the reduction of the immune ability of the living body ), A preventive or therapeutic agent for cancer, etc., or a functional food and a functional feed (feed additive) material.
図1は卵白の経口投与によるマウスでの黄色ブドウ球菌
に対する感染防御効果を示す図であり、図2は卵白の経
口投与によるマウスでの大腸菌に対する抗生物質オキシ
テトラサイクリンとの併用効果を示す図である。FIG. 1 is a diagram showing the effect of oral administration of egg white against Staphylococcus aureus in mice, and FIG. 2 is a diagram showing the effect of oral administration of egg white against Escherichia coli in mice in combination with the antibiotic oxytetracycline. .
Claims (1)
ァージ及び好中球活性化剤。1. A macrophage and neutrophil activator containing egg white.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2048396A JPH0699313B2 (en) | 1990-02-28 | 1990-02-28 | Macrophage and neutrophil activator |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2048396A JPH0699313B2 (en) | 1990-02-28 | 1990-02-28 | Macrophage and neutrophil activator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH03251537A JPH03251537A (en) | 1991-11-11 |
| JPH0699313B2 true JPH0699313B2 (en) | 1994-12-07 |
Family
ID=12802139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2048396A Expired - Fee Related JPH0699313B2 (en) | 1990-02-28 | 1990-02-28 | Macrophage and neutrophil activator |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0699313B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5741494A (en) * | 1993-04-07 | 1998-04-21 | Eisai Co., Ltd. | Immunopotentiative and infection-protective agent containing bacillus and egg white |
| JP5258582B2 (en) * | 2007-01-31 | 2013-08-07 | 株式会社糖鎖工学研究所 | Trehalose compound, method for producing the same, and immunostimulant containing the compound |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54145204A (en) * | 1978-05-01 | 1979-11-13 | Nisshin Flour Milling Co Ltd | Coccidiostatic agent |
| JPS6047243B2 (en) * | 1979-02-27 | 1985-10-21 | エーザイ株式会社 | immune booster |
| JPH0647550B2 (en) * | 1985-12-18 | 1994-06-22 | 日本化薬株式会社 | Antiviral agent |
-
1990
- 1990-02-28 JP JP2048396A patent/JPH0699313B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH03251537A (en) | 1991-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101228993B1 (en) | Fermentation and culture method, fermented plant extract, fermented plant extract powder and composition containing the fermented plant extract | |
| Aftabgard et al. | The combined efficiency of dietary isomaltooligosaccharides and Bacillus spp. on the growth, hemato-serological, and intestinal microbiota indices of Caspian brown trout (Salmo trutta caspius Kessler, 1877) | |
| Elshopakey et al. | Enhancement of immune response and resistance against Vibrio parahaemolyticus in kuruma shrimp (Marsupenaeus japonicus) by dietary supplementation of β-1, 4-mannobiose | |
| JP2009051836A (en) | Remedy | |
| Wu et al. | Dietary recombinant human lysozyme improves the growth, intestinal health, immunity and disease resistance of Pacific white shrimp Litopenaeus vannamei | |
| Meng et al. | Influence of low molecular weight chitooligosaccharides on growth performance and non-specific immune response in Nile tilapia Oreochromis niloticus | |
| EP1082908B1 (en) | Additives for crustacean or fish feeds and feeds | |
| JPH0838064A (en) | Feed capable of preventing infection of harmful bacterium | |
| Syed Raffic Ali et al. | Effect of dietary fructooligosaccharide supplementation on growth, body composition, hematological and immunological parameters of Asian seabass (Lates calcarifer) | |
| JPWO2001013925A1 (en) | therapeutic agent | |
| Ali et al. | Jerusalem artichoke enriched diet on growth performance, immuno-hematological changes and disease resistance against Aeromonas hydrophila in Asian seabass (Lates calcarifer) | |
| JPH0984529A (en) | Cattle and poultry feed containing mannan originated from microorganism | |
| KR100852744B1 (en) | Antimicrobial Composition Containing Brown Sea Extract | |
| JPH0699313B2 (en) | Macrophage and neutrophil activator | |
| JP3534792B2 (en) | Disease resistant feed | |
| JP2001008636A (en) | Feed composition for preventing infectious diseases | |
| JPH06178654A (en) | Feed for chicken | |
| CN100391446C (en) | Feeding method and feed | |
| JP2001309749A (en) | Feed additive for fishes | |
| JPH06263649A (en) | Immunopotenitator | |
| RU2632935C1 (en) | Method of increasing production quality while growing chickens-broilers | |
| EP4704598A1 (en) | Fucosylated mammalian milk oligosaccharide for use in the prevention or treatment of pneumonia | |
| JP5120971B2 (en) | Bone resorption inhibitor | |
| EP4704599A1 (en) | Fucosylated mammalian milk oligosaccharide for use in the prevention or treatment of shipping fever | |
| Rudoy et al. | Immunomodulatory feed additives for farm animals and fish |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081207 Year of fee payment: 14 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091207 Year of fee payment: 15 |
|
| LAPS | Cancellation because of no payment of annual fees |